TP53 mutations predict decitabine‐induced complete responses in patients with myelodysplastic syndromes
- 16 December 2016
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 176 (4), 600-608
- https://doi.org/10.1111/bjh.14455
Abstract
To identify the molecular signatures that predict responses to decitabine (DAC), we examined baseline gene mutations (28 target genes) in 109 myelodysplastic syndrome (MDS) patients at diagnosis. We determined that TP53 mutations predicted complete response (CR), as 10 of 15 patients (66·7%) who possessed TP53 mutations achieved a CR. Univariate and multivariate analyses showed that TP53 mutations are the only molecular signatures predictive of a CR to DAC in MDS. Among the ten patients with TP53 mutations who achieved a CR, nine presented with complex karyotypes due to abnormalities involving chromosome 5 and/or chromosome 7, and eight possessed monosomies. Although TP53 mutations were associated with a higher frequency of CRs, they were not associated with improved survival. Poor outcomes were attributed to early relapses and transformation to acute myeloid leukaemia after CR. Post-DAC therapy patient gene mutation profiles showed that most CR patients exhibited fewer gene mutations after achieving a CR. It seems that suppression of these gene mutations was facilitated by DAC, resulting in a CR. In summary, TP53 mutations might predict decitabine-induced complete responses in patients with MDS. DAC-induced responses may result from partial suppression of malignant clones containing mutated TP53 genes.Keywords
This publication has 29 references indexed in Scilit:
- p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemiaLeukemia, 2011
- IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosisHaematologica, 2010
- Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasmsLeukemia, 2010
- TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17pLeukemia, 2009
- Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaCancer, 2007
- Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcomeCancer, 2007
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982